Cyclic adenosine monophosphate signal pathway in targeted therapy of lymphoma

Chinese Medical Journal

Volumn 123, Issue 1, 2010, Pages 95-99

  Dou, Ai Xia ^a,b   Wang, Xin ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cyclic adenosine monophosphate; Lymphoma; Targeted therapy

Indexed keywords

CYCLIC AMP; PHOSPHODIESTERASE INHIBITOR; PROTEIN BNIP3; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CANCER CELL CULTURE; HUMAN; HUMAN CELL; LYMPHOMA; ONCOGENE C MYC; PROGNOSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; CYCLIC AMP; HUMANS; LYMPHOMA; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION;

EID: 74749107606     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.01.017     Document Type: Review

References (27)

1. Rall TW, Sutherlad EW. Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem 1958; 232: 1065-1076.
2. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J 2006; 393(Pt 1): 21-41.
3. Coffino P, Bourne HR, Tomkins GM. Mechanism of lymphoma cell death induced by cyclic AMP. Am J Pathol 1975; 81: 199-204.
4. Bodor J, Fehervari Z, Diamond B, Sakaguchi S. Regulatory T cell-mediated suppression: potential role of ICER. J Leukoc Biol 2007; 81: 161-167.
5. Mcknight GS. Cyclic AMP second messenger systems. Curr Opin Cell Biol 1991; 3: 213-217.
6. Jarnaess E, Taskén K. Spatiotemporal control of cAMP signaling processes by anchored signaling complexes. Biochem Soc Trans 2007; 35: 931-937.
7. Omori K, Kotera J. Overview of PDEs and their regulation. Circ Res 2007; 100: 309-327.
8. Hait WN, Weiss B. Increased cyclic nucleotide phosphodiesterase activity in leukaemic lymphocytes. Nature 1976; 259: 321-323.
9. Zhang L, Murray F, Zahno A, Kanter JR, Chou D, Suda R, et al. Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2008; 105: 19532-19537.
10. Zambon AC, Zhang L, Minovitsky S, Kanter JR, Prabhakar S, Salomonis N, et al. Gene expression patterns define key transcriptional events in cell-cycle regulation by cAMP and protein kinase A. Proc Natl Acad Sci U S A 2005; 102: 8561-8566.
11. Zhang L, Zambon AC, Vranizan K, Pothula K, Conklin BR, Insel PA, et al. Gene expression signatures of cAMP/protein kinase A (PKA)-promoted, mitochondrial-dependent apoptosis. Comparative analysis of wild-type and cAMP-deathless S49 lymphoma cells. J Biol Chem 2008; 283: 4304-4313.
12. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, et al. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005; 105: 308-316.
13. Kim SW, Rai D, McKeller MR, Aguiar RC. Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL. Blood 2009; 113: 6153-6160.
14. Uddin S, Hussain AR, Siraj AK, Manogaran PS, Al-Jomah NA, Moorji A, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006; 108: 4178-4186.
15. Hachem A, Gartenhaus RB. Oncogenes as molecular targets in lymphoma. Blood 2005; 106: 1911-1923.
16. Kim DH, Lerner A. Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood 1998; 92: 2484-2494.
17. Meyers JA, Taverna J, Chaves J, Makkinje A, Lerner A. Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells. Clin Cancer Res 2007; 13: 4920-4927.
18. Kiefer J, Okret S, Jondal M, McConkey DJ. Functional glucocorticoid receptor expression is required for cAMP-mediated apoptosis in a human leukemic T cell line. J Immunol 1995; 155: 4525-4528.
19. Tiwari S, Dong H, Kim EJ. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation. Biochem Pharmacol 2005; 69: 473-483.
20. Refojo D, Liberman AC, Giacomini D, Carbia Nagashima A, Graciarena M, Echenique C, et al. Integrating systemic information at the molecular level: cross-talk between steroid receptors and cytokine signaling on different target cells. Ann N Y Acad Sci 2003; 992: 196-204.
21. Baus E, Van Laethem F, Andris F, Rolin S, Urbain J, Leo O. Dexamethasone increases intracellular cyclic AMP concentration in murine T lymphocyte cell lines. Steroids 2001; 66: 39-47.
22. Liu XH, Zheng XF, Wang YL Inhibitive effect of 3-bromopyruvic acid on human breast cancer MCF-7 cells involves cell cycle arrest and apoptotic induction. Chin Med J 2009; 122: 1681-1685.
23. Zhang L, Insel PA. Bcl-2 protects lymphoma cells from apoptosis but not growth arrest promoted by cAMP and dexamethasone. Am J Physiol Cell Physiol 2001; 281: C1642-C1647.
24. Moon EY, Lerner A. PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 2003; 101: 4122-4130.
25. Zhang L, Insel PA. The pro-apoptotic protein Bim is a convergence point for cAMP/protein kinase A- and glucocorticoid-promoted apoptosis of lymphoid cells. J Biol Chem 2004; 279: 20858-20865.
26. Zhou B, Li F, Chen H, Song J. The modulation of apoptosis by cyclic AMP involves Akt and epidermal growth factor receptor. Int J Biochem Cell Biol 2005; 37: 1483-1495.
27. Albert DA. The effect of cyclic-AMP on the regulation of c-myc expression in T lymphoma cells. J Clin Invest 1995; 95: 1490-1496.